Patent JPH01137221A successfully refreshed from Google Patents.
US4844909A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release hydromorphone composition
Assignee: Purdue Pharma LP
•
Filing: 1987-10-26
•
Granted: 1989-07-04
•
Expires: 2007-10-26
Abstract
Abstract A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% ad 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
Inventors
- 👤 Robert S. Goldie
- 👤 Sandra T. A. Malkowska
- 👤 Stewart T. Leslie
- 👤 Ronald B. Miller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 23:26
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2013; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/2022; A61K9/205; A61K9/2054; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5036; A61K9/5042; A61K9/5047
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
162 words
A solid, controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromophone or a salt thereof in a matrix, comprising at least one water soluble hydroxyalkylcellulose, at least one C 12 to C 36 aliphatic alcohol and, optionally, at least one polyalkylene glycol, wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55%(by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between 1.6 and 7.2 and chosen such that the peak plasm level of hyromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
Claim 2
Dependent Claim
162 words
A solid, controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromophone or a salt thereof in a matrix, comprising at least one water soluble hydroxyalkylcellulose, at least one C 12 to C 36 aliphatic alcohol and, optionally, at least one polyalkylene glycol, wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55%(by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between 1.6 and 7.2 and chosen such that the peak plasm level of hyromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
Claim 3
Dependent Claim
24 words
A dosage form according to claim 1 wherein the at least one water soluble hydroxyalkylcellulose comprises a hydroxy C 1 -C 6 alkyl cellulose.
Claim 4
Dependent Claim
22 words
A dosage form according to claim 1 wherein the at least one hydroxyalkyl cellulose is selected from hydroxypropyl cellulose, hydroxypropylmethylcellulose and hydroxyethylcellulose.
Claim 5
Dependent Claim
15 words
A dosage form according to claim 3 wherein the at least one hydroxyalkylcellulose comprises hydroxyethylcellulose.
Claim 6
Dependent Claim
24 words
A dosage form according to claim 1 wherein the dosage form contains between 5% and 25% (by weight) of the at least one hydroxyalkylcellulose.
Claim 7
Dependent Claim
24 words
A dosage form according to claim 5 wherein the dosage form contains between 6.25% and 15% (by weight) of the at least one hydroxyalkylcellulose.
Claim 8
Dependent Claim
20 words
A dosage form according to claim 1 wherein the aliphatic alcohol comprises a C 14 to C 22 aliphatic alcohol.
Claim 9
Dependent Claim
25 words
A dosage form according to claim 1 wherein the aliphatic alcohol is selected from lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol and cetostearyl alcohol.
Claim 10
Dependent Claim
19 words
A dosage form according to claim 8 wherein the aliphatic alcohol is selected from cetyl alcohol and cetostearyl alcohol.
Claim 11
Dependent Claim
40 words
A dosage form according to claim 1 wherein the dosage form contains between 20% and 50% (by weight) of the at least one fatty alcohol or of the at least one fatty alcohol and the at least one polyalkylene glycol.
Claim 12
Dependent Claim
40 words
A dosage form according to claim 10 wherein the dosage form contains between 25% and 45% (by weight) of the at least one fatty alcohol or of the at least one fatty alcohol and the at least one polyalkylene glycol.
Claim 13
Dependent Claim
29 words
A dosage form according to claim 1 wherein the ratio of the at least one hydroxyalkylcellulose to the at least one aliphatic alcohol/polyalkylene glycol is between 1:2 and 1:4.
Claim 14
Dependent Claim
15 words
A dosage form according to claim 12 wherein the ratio is between 1:3 and 1:4.
Claim 15
Dependent Claim
160 words
A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100rpm at 900ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, betweeen 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form, said dosage form being in the form of film coated spheroids wherein the spheroid matrix comprises a non-water soluble spheronising agent.
Claim 16
Dependent Claim
160 words
A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100rpm at 900ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, betweeen 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form, said dosage form being in the form of film coated spheroids wherein the spheroid matrix comprises a non-water soluble spheronising agent.
Claim 17
Dependent Claim
14 words
A dosage form according to claim 14 wherein the spheroid matrix comprises microcrystalline cellulose.
Claim 18
Dependent Claim
19 words
A dosage form according to claim 15 wherein the spheroid matrix comprises microcrystalline cellulose and a water insoluble polymer.
Claim 19
Dependent Claim
156 words
A solid, controlled release, oral dosage form comprising film coated spheroids, the spheroids comprising a therapeutically effective amount of hydromorphone or a salt thereof incorporated in a spheroid matrix comprising microcrystalline cellulose and a water soluble polymeric binder, wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
Claim 20
Dependent Claim
156 words
A solid, controlled release, oral dosage form comprising film coated spheroids, the spheroids comprising a therapeutically effective amount of hydromorphone or a salt thereof incorporated in a spheroid matrix comprising microcrystalline cellulose and a water soluble polymeric binder, wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-03 | 1993-01-02 | 1993-07-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-03 | 1997-01-02 | 1997-07-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-03 | 2001-01-02 | 2001-07-04 | $7700.00 | Window Closed / Lapsed |